GSK 4771261
Alternative Names: GSK-4771261Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator GSK
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease
Most Recent Events
- 11 Dec 2024 Phase-I clinical trials in Autosomal dominant polycystic kidney disease in United Kingdom (unspecified route),
- 09 Oct 2024 GSK plans a phase I study for Autosomal dominant polycystic kidney disease in an unknown location (NCT06625476)
- 09 Oct 2024 Preclinical trials in Autosomal dominant polycystic kidney disease in United Kingdom (unspecified route)